On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Initiates Program to Treat Patients with Pulmonary Complications from COVID-19 Infection with TNF Inhibitor “DN-TNF” Platform

Company: INmune Bio Inc. (INMB)
Category: News

INmune Bio (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, on Monday announced the initiation of a therapeutic program to treat patients with pulmonary complications from COVID-19 infection with its dominant-negative TNF inhibitor (“DN-TNF”) platform. According to the update, the program targets patients admitted to the hospital with hypoxia who do not yet require intensive respiratory support. If successful, DN-TNF treatment should decrease the need to transfer patients to the ICU and the need for mechanical ventilation. “In response to reports highlighting the role of TNF in the cytokine storm of COVID-19 and the Lancet article, ‘Trials of anti-tumor necrosis factor therapy for COVID-19 are urgently needed’ published earlier, INmune Bio is initiating a program to treat patients with pulmonary complications from COVID-19 infection,” INmune Bio CEO and Chief Medical Officer RJ Tesi MD stated in the news release. “DN-TNF targets one of the main cytokines involved in cytokine storm without causing immunosuppression. The trial targets patients not yet in ICU or on mechanical ventilation in an attempt to keep them from needing these scarce resources.”

To view the full press release, visit http://nnw.fm/AyR2w

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03(TM)), Alzheimer’s (XPro595), and NASH (LIVNate(TM)). The Natural Killer Cell Priming Platform includes INKmune(TM) aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.  To learn more, please visit www.INmuneBio.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217